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A B S T R A C T
In human organism development is a very complex and highly regulated system that enables the functional balance 
of each organ in a whole body. Disorders and tumor micro-environment weaken host immune system that is not able to 
recognize the tumor as a unknown body and fi ght against its uncontrollable forces. Tumor avoids the immune system in 
a way that promotes immunosuppression and orientation cytokine production towards Th2 immune responses which are 
responsible for infection appearances. Some of infectious agents (viruses) can cause oncogene activation and inhibition of 
tumor suppressor genes. It is also known that oncology treatment can be detrimental to the host immune system. The drugs 
or radiation can activate different signaling pathways which lead to a vicious circle from which there is no return. Ex-
perimental models of tumor biology and molecular events in vivo are patients who have multiple primary cancers (MPC) 
diagnosed during life. Such patients confi rm the complexity of disorders that occur in the cell and explain all the infl u-
ences and contributions to developmental tumor cascade.
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Introduction
In the tumor cell, the major cellular processes are dis-
turbed at the level of genes, chromosomes, signaling path-
ways, immune system. Disorders present at the level of 
the genes are point mutations, translocations, deletions 
and amplifi cation. These changes mostly lead to the ap-
pearance of gain or loss of chromosome, microsatellite 
instability (MSI), DNA (Deoxiribonucleic Acid), mutation 
in DNA repair mechanisms and telomere maintenance1. 
Patients who have multiple tumors diagnosed during life 
can be in vivo models and they can show us complexity of 
tumor biology and molecular events like investigations in 
vitro on experimental models. Multiple primary cancers 
were fi rst described by Billroth in 18892. In 1932, Warren 
and Gates published the fi rst study of 1,259 patients with 
multiple neoplasms3. Ever since, there have been numer-
ous reports addressing the occurrence of second primary 
neoplasms. Synchronous cancers occur at the same time 
or within an interval of two months, while metachronous 
cancers follow in sequence and more than two months 
apart. There is the most used classifi cation of multiple 
tumors (Table 1)4.
Epidemiology and Etiology of MPC
In the literature the prevalence of MPC is estimated 
between 0.73% and 11.7% and the incidence is increasing 
with age5. Breast cancer was found to be one of the most 
frequent malignant tumors associated with other primary 
cancers. The most frequent malignant associations are 
breast-breast, breast-endometrium and breast-ovary. It 
was showed that twenty-one patients developed the fi rst 
breast cancer at an early age under 50 years, before meno-
pause6. So it is suggested that Oncotype Dx testing is use-
ful in MPC. Oncotype Dx testing on multiple primary 
breast cancers altered management in regards to chemo-
therapy recommendations and should be considered for 
multiple primary breast cancers. The median period of 
time between the two primary cancers was 10.69 years. 
The most frequent synchronous malignant tumors are 
breast cancers, mostly because of the use of mammogra-
phy as a screening method. Usually the metachronous 
breast malignant lesions were discovered because of the 
follow-up of the fi rst malignant tumor7. Qualitatively, 
there seems to be a greater difference in genetic profi le in 
tumors appearing simultaneously on different breasts 
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more than 30 genes are known to be related to the occur-
rence of malignant tumors, and those closely related to 
increased risk for MPCare tumor suppressor genes and 
DNA repairing genes. Latest studies found that genomic 
instability and changes in gene expression profi le (such as 
tumor suppressor genes and DNA epairing genes) and 
even mutation and deletion of chromosomes were closely 
related to the occurrence of multiple primary cancers5,6.
Breast cancer in MPC
The epidermal growth factor receptor (EGFR) is impli-
cated in breast cancer progression and is associated with 
an aggressive phenotype. The presence of EGFR muta-
tions in exons 18–21 in breast cancer, as in non-small-cell 
lung cancer7. 50% of TP53 (mutations within the TP53-
coding region), associated lung cancers were squamous 
cell carcinoma and 20% of TP53 mutations associated 
with ‘high differentiation’ cancers and 25.9% of TP53 mu-
tations were ‘mid differentiation’ cancers12. Data suggest-
ed that EGFR mutations in concert with P53 mutations 
accelerate cancer development and lead to evolution of 
therapeutic resistance13. In the second patient in case re-
port 2 all four tumors are associated with mutation of 
p5314,15. In CLL, p53 mutation is much more frequent in 
patients who have received chemotherapy prior to sample 
extraction16,17. The excessive skin melanoma in breast can-
cer survivors was attributed to the relationship with 
Breast Cancer genes 2 (2 BRCA2) and cyclin-dependent 
kinase inhibitor 2A (CDKN2A) mutation-positive pa-
tients. CDKN2 has a critical target or targets in the reti-
noblastoma (RB) pathway which mutations are associated 
with breast cancer, melanoma and lung cancer17. While 
most human solid tumors neutralize this tumor-suppres-
sive pathway at the level of p53 itself (TP53) melanoma 
provides a notable exception to this rule. It became clear 
that functional inactivation of p53 could be achieved by 
the melanoma cell through other signaling pathways. In 
fact, concomitant deletion of the CDKN2A locus does occur 
in the face of activating Cyclin-dependent kinase 4 
(CDKN4) mutations suggesting that abrogation of the RB 
pathway through cyclin dependent kinases mediated 
mechanisma is still insuffi ciently explored18.
MSI was noticed to occur more frequently in cases of 
MPC than in sporadic cancers19. Cancer does not occur 
when compared to multiple tumors on the same breast. 
There was no association between distance between tu-
mors and difference in Oncotype Dx scores for tumors on 
the same breast8. New South Wales Central Cancer Reg-
istry revealed an increased risk between 1972–1991 to 
develop a second primary after a colon cancer: small bow-
el cancers in both sexes, prostate and kidney cancer in 
men, breast, endometrial, ovarian cancer and thyroid can-
cer in women. After a rectal cancer, the risk is increased 
for another colon, prostate and pancreas cancer6. In Japan 
other primaries are described as well (stomach, lung, pros-
tate, larynx, liver, esophagus and urinary bladder in men; 
uterus, stomach, breast, and liver in women). Also, in the 
colorectal synchronous cancers group there were patients 
diagnosed with pancreatic cancer and prostate cancer, as 
other new primaries9. Carcinogenic insults, such as to-
bacco and alcohol, may increase the likelihood of multiple 
independent malignant foci developing in the mucosa epi-
thelium. Smoking-related cancers, prostate cancers and 
renal cell carcinoma are most commonly associated with 
MPC10. Head and neck cancer survivors are at an in-
creased risk of developing another cancer of the respira-
tory or digestive tract11. A ‘fi eld cancerization effect’ was 
assumed to explain this phenomenon, with carcinogens to 
which the organ has been exposed initiating the prolifera-
tion of numerous clones of cells12. The Japanese population 
appears to have a higher likelihood of developing MPC. 
This may be caused by genetic susceptibility, longer aver-
age life span or medical advances in chemotherapy and 
radiotherapy. The increasing effectiveness of cancer ther-
apies and the improvement of diagnostic tools have led to 
better survival rates among cancer patients. The risk of 
developing any second cancer 3.8 % at 10 years versus 7% 
at 15 years for patients receiving a doxorubicin-based 
regimen for breast cancer5–7.
Cellular and Molecular Disorders in MPC
The pathogenic mechanisms of multiple primary lung 
cancer are rather complicated, but currently available 
clinical and fundamental study data are rare. Analyses 
on the main reasons for increased incidence of multiple 
primary lung cancer can help improve the understanding 
on the pathogenic mechanisms of the disease. Besides en-
vironmental factors, genetic factors also have important 
role in the occurrence of malignant tumors. At present, 
TABLE 1
CLASSIFICATION OF MULTIPLE TUMORS
GROUP I multiple primary tumors occurring in organs with the same histology:
– including cancers that occur in the same tissue and organ (Group IA).
– including cancers that are from the same tissue and different organs (Group IB)
– including cancers that occur in bilateral organs (Group IC).
GROUP II multiple primary tumors originating from different tissues
GROUP III multiple tumor originating from different tissues and organs that concurrently exist with group I forming 
multiple primary cancer of three or more cancers. 
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from a single gene mutation in a single gene. Instead, the 
development of cancer involves multiple mutations within 
several key genes, including mutations in proto-oncogenes, 
tumor suppressor genes, and DNA repair genes1. So we 
can assume that when one mutation happened it can lead 
to numeral different tumors associated with that muta-
tion. The drugs or radiation can activate different signal-
ing pathways which lead to a vicious circle from which 
there is no return. It is also known that tumor evade host 
immune system and that our treatments can cause deeper 
host immunity deprivation20. Lian et al. showed 51-year-
old female developed 6 metachronous primary malignant 
neoplasms in a period of 10 years. This patient had no 
familial or hereditary tendencies but, defi nite impairment 
of the cellular immunity had been identifi ed21. Merkel cell 
carcinoma frequently appers in immunocompromised ex-
pecially in recipient of great number of chemotherapy pro-
tocols and radiotherapy and in patients with polyoma vi-
rus infection22,23. Anaplastic lymphoma kinase (ALK-1) 
mutation associated with non-Hodgkin lymphoma. ALK 
protein was detected with high frequency in Merkel cell 
carcinomas and was useful in distinguishing Merkel cell 
carcinoma from small cell lung carcinoma24. It was shown 
that one reason may be our chemotherapy or radiotherapy 
used for the fi rst malignancy3. That treatment could result 
some damage of specifi c regions of DNA with chromosome 
rearrangement or loss responsible for tumorigenesis5.
Conclusion
Most patients with MPC are geriatric. The majority of 
the patients with quadruple cancers present with breast 
and upper aero-digestive tumors25. The reports on patients 
with multiple primaries include patients at an earlier 
stage 0 (carcinoma in situ), while others limit the study to 
invasive cancers (stage I and above)26. Patients with mul-
tiple primaries are usually of Caucasian ancestry, have 
less aggressive malignancies, present at earlier stages of 
disease, and frequently have a strong family history of 
similar malignancies and predisposition genes in Cauca-
sians. They tend to have cancers with indolent clinical 
behavior and longer overall survival, especially in those 
developing second malignancies more than 5 years after 
the initial primary diagnosis14. The possibility of multiple 
primary malignancies should always be considered during 
the treatment and follow-up of cancer patients, especially 
those of Caucasian ancestry and those having a strong 
family history of cancer. Because of advances in the early 
detection, treatment, and supportive care for cancer, the 
number of cancer survivors has been gradually increasing, 
and this has led to an increase in the possible occurrence 
of subsequent malignancies3. According to the Surveil-
lance, Epidemiology and End Results cancer registries of 
the National Cancer Institute, cancer survivors had a 14% 
higher risk of developing a new malignancy than would 
have been expected in the general population6.
Concluding Remarks
The body is made up of a community of individual cells, 
each of which has a specifi c job to ensure that the com-
munity functions correctly. Cancer is not one disease, but 
literally hundreds of different diseases1. Cancer forms 
when genes within a normal cell are damaged and mu-
tated. The development of multiple primaries may possibly 
be related to genetic disorders of known or an unidentifi ed 
nature. Because of advances in the early detection, treat-
ment, and supportive care for cancer, the number of cancer 
survivors has been gradually increasing, and this has led 
to an increase in the possible occurrence of subsequent 
malignancies2. The early diagnosis of secondary malig-
nancies should not be neglected in patients treated for a 
primary malignancy, especially when the long clinical pe-
riod before the diagnosis of subsequent tumors is taken 
into consideration. With careful monitoring, secondary 
tumors can be detected earlier, and, with appropriate in-
tervention, might be better managed, without compromis-
ing survival. Experimental models of tumor biology and 
molecular events in vivo are patients who have multiple 
tumors diagnosed during life. Such patients confi rm the 
complexity of disorders that occur in the cell and explain 
all the infl uences and contributions to developmental tu-
mor cascade6.
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POKAZATELJI MOLEKULARNIH POREMEĆAJA U RAZVOJU MULTIPLIH TUMORA
S A Ž E T A K
Razvoj organizma u čovjeka vrlo je složen i visoko reguliran sustav koji omogućava funkcionalnu ravnotežu svakog 
organa u cjelini. Glavni stanični procesi u tumorskoj stanici poremećeni su na razini gena, kromosoma, signalnih put-
ova, imunološkog sustava itd. Na razini gena prisutni su poremećaji u smislu točkastih mutacija, translokacija, ampli-
fi kacija i delecija. Navedeno vodi ka nastanku viška ili manjka kromosoma, mikrosatelitnih nestabilnosti, poremećaja 
mehanizama popravka DNK (deoksiribonukleinkse kiseline), dugovječno održavanje telomeraza i slično. Poremećaj 
stanica vodi ka slabljenju imunološkog sustava domaćina koji bi trebao prepoznati tumor kao nepoznato tijelo i boriti se 
protiv njegove nekontrolirane snage. Tumor izbjegava imunološki sustav na način da potiče imunosupresiju tj. orijentira 
imunološki odgovor ka stvaranju Th2 citokina. Tumorski mikrookoliš omogućava nastanak i rasplamsavanje infekcija 
(npr. virusa) koji potiču onkogene a koče tumor supresor gene. Također je poznato da i onkološka terapija dodatno može 
smanjivati imunitet domaćina i aktivirati signalne putove koji naše bolesnike vode u začarani krug iz kojeg nema 
povratka. Eksperimentalni modeli tumorske biologije i molekularnih zbivanja in vivo jesu bolesnici koji imaju multiple 
tumore dijagnosticirane tijekom života. Takvi bolesnici nam potvrđuju svu složenost poremećaja koji nastanu u stanici 
i što sve može utjecati i doprinositi nezaustavljivoj tumorskoj kaskadi.
